Skip to content

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01089751
Enrollment
322
Registered
2010-03-19
Start date
2010-03-31
Completion date
2012-06-30
Last updated
2013-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder

Brief summary

This study will investigate the safety and efficacy of Sanctura XR (trospium chloride) daily in reducing urgency, urinary frequency and urinary urge incontinence in female patients with incontinence refractory to Detrol LA (tolterodine tartrate extended release) 4 mg therapy.

Interventions

Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks

DRUGplacebo

Placebo once daily on an empty stomach for 14 weeks.

Sponsors

Allergan
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Taking Detrol® LA 4mg daily for a minimum of 1 month prior to Screening/Qualification * Overactive Bladder syndrome with urgency, urinary frequency and urgency urinary incontinence * Taking five or more concomitant medications (may be prescription, non-prescription, or supplement/vitamin) daily for indications other than Overactive Bladder (OAB).

Exclusion criteria

* Predominant stress or insensate incontinence * History of neurogenic bladder * Two urinary tract infections in the last six months * Gastric by-pass (Roux-en-Y) surgery (adjustable gastric banding is allowed) * Donated \>500mL blood in the 30 days prior to the screening visit

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Patients Continent (PPC)Week 14PPC is the percentage of patients with complete continence (without any urgency urinary incontinence episodes) during the 3-day bladder diary period associated with the Week 14 visit.

Secondary

MeasureTime frameDescription
Change From Baseline in Nocturic Toilet VoidsBaseline, Week 14A nocturic (nighttime) toilet void is identified if the patient marks Yes for both Toilet Voiding and Sleep Interruption in the 3-day bladder diary. The daily average number of nocturic toilet voids is obtained as the sum of all nighttime toilet voids over the 3-day bladder diary period divided by number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer nocturic toilet voids) indicated improvement.
Change From Baseline in Urgency-Related Toilet VoidsBaseline, Week 14Urgency-related toilet void (or urinary urgency) is identified if the patient marks Yes for both Urgency Association Void and Toilet Voiding in the 3-day bladder diary. The daily average number of urgency-related voids is calculated as the sum of all urgency episodes over the 3-day bladder diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer urgency related toilet voids) indicated improvement.
Change From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)Baseline, Week 14The OAB-SCS is derived from the 3-day bladder diary which includes: 1) 24-hour voiding frequency; 2) the Indevus Urgency Severity Scale (IUSS) Score (0=no urgency, 1=aware of urgency but is tolerable, 2=urgency discomfort interferes with activities/tasks, 3=extreme urgency discomfort that abruptly stops activities/tasks associated with each toilet void); and 3) the frequency of Urgency Urinary Incontinence episodes. Each toilet void is then assigned a point value from 1 (IUSS Score=0) to 5 (UUI episode not associated with a toilet void). The daily average OAB-SCS is then calculated based on the diary entries and assigned point values. The lowest possible daily average OAB-SCS is 0 (corresponding to no urgency in every void). There is no upper limit since the score is based on the number of voids per day. Scores \<= 30 indicate mild OAB, scores \> 30 to 39 indicate moderate OAB, and scores \>= 40 indicate severe OAB. A negative change from Baseline indicated improvement.
Change From Baseline in Continent Days Per Week (CDW)Baseline, Week 14Continent Days per Week is the average of the number of times an individual has no incontinence episodes in a day within the 3-day collection period calculated as 7 x (number of dry days within the 3-day diary period) divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A positive change from Baseline (more continent/fewer incontinent days per week ) indicated improvement.
Change From Baseline in Urgency SeverityBaseline, Week 14The urgency severity per toilet void is based on the Indevus Urgency Severity Scale (IUSS). The patient recorded urinary urgency severity in a 3-day bladder diary using a 4-point scale: 0=None-no urgency (best), 1=Slight-aware of urgency but is tolerable, 2=Moderate-urgency discomfort interferes with activities/tasks, 3=Severe-extreme urgency discomfort that abruptly stops activities/tasks (worst). Urgency Severity is calculated as the sum of all IUSS scores during the 3-day diary period divided by the number of toilet voids recorded during that period. A negative change from Baseline indicated improvement.
Change From Baseline in Urgency Urinary Incontinence (UUI)Baseline, Week 14Urgency urinary incontinence is identified if the patient marks Yes for both Accidental Leakage and Urgency Associated Void in the 3-day bladder diary, and the Urgency Severity score is ≥ 1. Average daily episodes of UUI is calculated as the sum of all UUI episodes over 3-day diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline indicated improvement.
Change From Baseline in Voided VolumeBaseline, Week 14Average volume of urine voided per toilet void is calculated by total volume collected in a 24-hour diary period divided by the number of individual entries of volume voided in that period. A positive change from Baseline (greater volume voided) indicated improvement. A negative change from Baseline (less volume voided) indicated a worsening.

Countries

United States

Participant flow

Participants by arm

ArmCount
Sanctura XR®
Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks.
163
Placebo
Placebo once daily on an empty stomach for 14 weeks.
159
Total322

Baseline characteristics

CharacteristicSanctura XR®PlaceboTotal
Age Continuous56.3 Years56.0 Years56.1 Years
Sex: Female, Male
Female
163 Participants159 Participants322 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
20 / 1628 / 158
serious
Total, serious adverse events
2 / 1623 / 158

Outcome results

Primary

Percentage of Patients Continent (PPC)

PPC is the percentage of patients with complete continence (without any urgency urinary incontinence episodes) during the 3-day bladder diary period associated with the Week 14 visit.

Time frame: Week 14

Population: Modified intent-to-treat population included all randomized participants who were incontinent at Baseline with at least one urinary episode marked Yes for both Accidental leakage and Urgency associated void, and an Urgency severity rating ≥ 1 in the bladder diary.

ArmMeasureValue (NUMBER)
Sanctura XR®Percentage of Patients Continent (PPC)34.6 Percentage of participants
PlaceboPercentage of Patients Continent (PPC)17.1 Percentage of participants
Secondary

Change From Baseline in Continent Days Per Week (CDW)

Continent Days per Week is the average of the number of times an individual has no incontinence episodes in a day within the 3-day collection period calculated as 7 x (number of dry days within the 3-day diary period) divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A positive change from Baseline (more continent/fewer incontinent days per week ) indicated improvement.

Time frame: Baseline, Week 14

Population: Modified intent-to-treat population included all randomized participants who were incontinent at Baseline with at least one urinary episode marked Yes for both Accidental leakage and Urgency associated void, and an Urgency severity rating ≥ 1 in the bladder diary.

ArmMeasureGroupValue (MEAN)Dispersion
Sanctura XR®Change From Baseline in Continent Days Per Week (CDW)Baseline0.8 Continent days per weekStandard Deviation 1.46
Sanctura XR®Change From Baseline in Continent Days Per Week (CDW)Change from Baseline at Week 142.6 Continent days per weekStandard Deviation 2.96
PlaceboChange From Baseline in Continent Days Per Week (CDW)Baseline1.0 Continent days per weekStandard Deviation 1.52
PlaceboChange From Baseline in Continent Days Per Week (CDW)Change from Baseline at Week 141.3 Continent days per weekStandard Deviation 2.73
Secondary

Change From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)

The OAB-SCS is derived from the 3-day bladder diary which includes: 1) 24-hour voiding frequency; 2) the Indevus Urgency Severity Scale (IUSS) Score (0=no urgency, 1=aware of urgency but is tolerable, 2=urgency discomfort interferes with activities/tasks, 3=extreme urgency discomfort that abruptly stops activities/tasks associated with each toilet void); and 3) the frequency of Urgency Urinary Incontinence episodes. Each toilet void is then assigned a point value from 1 (IUSS Score=0) to 5 (UUI episode not associated with a toilet void). The daily average OAB-SCS is then calculated based on the diary entries and assigned point values. The lowest possible daily average OAB-SCS is 0 (corresponding to no urgency in every void). There is no upper limit since the score is based on the number of voids per day. Scores \<= 30 indicate mild OAB, scores \> 30 to 39 indicate moderate OAB, and scores \>= 40 indicate severe OAB. A negative change from Baseline indicated improvement.

Time frame: Baseline, Week 14

Population: Modified intent-to-treat population included all randomized participants who were incontinent at Baseline with at least one urinary episode marked Yes for both Accidental leakage and Urgency associated void, and an Urgency severity rating ≥ 1 in the bladder diary.

ArmMeasureGroupValue (MEAN)Dispersion
Sanctura XR®Change From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)Baseline24.6 Score on a scaleStandard Deviation 9.07
Sanctura XR®Change From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)Change from Baseline at Week 14-6.5 Score on a scaleStandard Deviation 10.23
PlaceboChange From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)Baseline23.7 Score on a scaleStandard Deviation 10.7
PlaceboChange From Baseline in Daily Average Overactive Bladder-Symptom Composite Score (OAB-SCS)Change from Baseline at Week 14-3.4 Score on a scaleStandard Deviation 11.44
Secondary

Change From Baseline in Nocturic Toilet Voids

A nocturic (nighttime) toilet void is identified if the patient marks Yes for both Toilet Voiding and Sleep Interruption in the 3-day bladder diary. The daily average number of nocturic toilet voids is obtained as the sum of all nighttime toilet voids over the 3-day bladder diary period divided by number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer nocturic toilet voids) indicated improvement.

Time frame: Baseline, Week 14

Population: Modified intent-to-treat population included all randomized participants who were incontinent at Baseline with at least one urinary episode marked Yes for both Accidental leakage and Urgency associated void, and an Urgency severity rating ≥ 1 in the bladder diary.

ArmMeasureGroupValue (MEAN)Dispersion
Sanctura XR®Change From Baseline in Nocturic Toilet VoidsBaseline2.2 Nocturic toilet voidStandard Deviation 1.4
Sanctura XR®Change From Baseline in Nocturic Toilet VoidsChange from Baseline at Week 14-0.6 Nocturic toilet voidStandard Deviation 1.51
PlaceboChange From Baseline in Nocturic Toilet VoidsBaseline2.3 Nocturic toilet voidStandard Deviation 1.41
PlaceboChange From Baseline in Nocturic Toilet VoidsChange from Baseline at Week 14-0.3 Nocturic toilet voidStandard Deviation 1.42
Secondary

Change From Baseline in Urgency-Related Toilet Voids

Urgency-related toilet void (or urinary urgency) is identified if the patient marks Yes for both Urgency Association Void and Toilet Voiding in the 3-day bladder diary. The daily average number of urgency-related voids is calculated as the sum of all urgency episodes over the 3-day bladder diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline (fewer urgency related toilet voids) indicated improvement.

Time frame: Baseline, Week 14

Population: Modified intent-to-treat population included all randomized participants who were incontinent at Baseline with at least one urinary episode marked Yes for both Accidental leakage and Urgency associated void, and an Urgency severity rating ≥ 1 in the bladder diary.

ArmMeasureGroupValue (MEAN)Dispersion
Sanctura XR®Change From Baseline in Urgency-Related Toilet VoidsBaseline7.6 Toilet voidStandard Deviation 3.36
Sanctura XR®Change From Baseline in Urgency-Related Toilet VoidsChange from Baseline at Week 14-2.3 Toilet voidStandard Deviation 3.78
PlaceboChange From Baseline in Urgency-Related Toilet VoidsBaseline7.5 Toilet voidStandard Deviation 3.62
PlaceboChange From Baseline in Urgency-Related Toilet VoidsChange from Baseline at Week 14-1.6 Toilet voidStandard Deviation 3.87
Secondary

Change From Baseline in Urgency Severity

The urgency severity per toilet void is based on the Indevus Urgency Severity Scale (IUSS). The patient recorded urinary urgency severity in a 3-day bladder diary using a 4-point scale: 0=None-no urgency (best), 1=Slight-aware of urgency but is tolerable, 2=Moderate-urgency discomfort interferes with activities/tasks, 3=Severe-extreme urgency discomfort that abruptly stops activities/tasks (worst). Urgency Severity is calculated as the sum of all IUSS scores during the 3-day diary period divided by the number of toilet voids recorded during that period. A negative change from Baseline indicated improvement.

Time frame: Baseline, Week 14

Population: Modified intent-to-treat population included all randomized participants who were incontinent at Baseline with at least one urinary episode marked Yes for both Accidental leakage and Urgency associated void, and an Urgency severity rating ≥ 1 in the bladder diary.

ArmMeasureGroupValue (MEAN)Dispersion
Sanctura XR®Change From Baseline in Urgency SeverityBaseline1.4 Score on a scaleStandard Deviation 0.6
Sanctura XR®Change From Baseline in Urgency SeverityChange from Baseline at Week 14-0.4 Score on a scaleStandard Deviation 0.67
PlaceboChange From Baseline in Urgency SeverityBaseline1.3 Score on a scaleStandard Deviation 0.56
PlaceboChange From Baseline in Urgency SeverityChange from Baseline at Week 14-0.3 Score on a scaleStandard Deviation 0.6
Secondary

Change From Baseline in Urgency Urinary Incontinence (UUI)

Urgency urinary incontinence is identified if the patient marks Yes for both Accidental Leakage and Urgency Associated Void in the 3-day bladder diary, and the Urgency Severity score is ≥ 1. Average daily episodes of UUI is calculated as the sum of all UUI episodes over 3-day diary period divided by the number of valid diary days with at least one valid bladder diary entry during the 3-day period. A negative change from Baseline indicated improvement.

Time frame: Baseline, Week 14

Population: Modified intent-to-treat population included all randomized participants who were incontinent at Baseline with at least one urinary episode marked Yes for both Accidental leakage and Urgency associated void, and an Urgency severity rating ≥ 1 in the bladder diary.

ArmMeasureGroupValue (MEAN)Dispersion
Sanctura XR®Change From Baseline in Urgency Urinary Incontinence (UUI)Baseline2.9 UUI episodesStandard Deviation 2.99
Sanctura XR®Change From Baseline in Urgency Urinary Incontinence (UUI)Change from Baseline at Week 14-1.1 UUI episodesStandard Deviation 2.24
PlaceboChange From Baseline in Urgency Urinary Incontinence (UUI)Baseline3.0 UUI episodesStandard Deviation 2.72
PlaceboChange From Baseline in Urgency Urinary Incontinence (UUI)Change from Baseline at Week 14-0.6 UUI episodesStandard Deviation 2.22
Secondary

Change From Baseline in Voided Volume

Average volume of urine voided per toilet void is calculated by total volume collected in a 24-hour diary period divided by the number of individual entries of volume voided in that period. A positive change from Baseline (greater volume voided) indicated improvement. A negative change from Baseline (less volume voided) indicated a worsening.

Time frame: Baseline, Week 14

Population: Modified intent-to-treat population included all randomized participants who were incontinent at Baseline with at least one urinary episode marked Yes for both Accidental leakage and Urgency associated void, and an Urgency severity rating ≥ 1 in the bladder diary.

ArmMeasureGroupValue (MEAN)Dispersion
Sanctura XR®Change From Baseline in Voided VolumeBaseline183.5 cubic centimeters (cc)Standard Deviation 79.78
Sanctura XR®Change From Baseline in Voided VolumeChange from Baseline at Week 1420.6 cubic centimeters (cc)Standard Deviation 89.62
PlaceboChange From Baseline in Voided VolumeBaseline187.4 cubic centimeters (cc)Standard Deviation 78.76
PlaceboChange From Baseline in Voided VolumeChange from Baseline at Week 14-8.0 cubic centimeters (cc)Standard Deviation 71.56

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026